Disease × agent evidence record

Valsartan for Chronic Kidney Disease: evidence, trials and status

Valsartan has both completed registered trials and synthesis-level publications linked to Chronic Kidney Disease. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit.

8 registered trials 1 recruiting 13 publications Evidence tier A · Strong Score 75.0
Research Tracker › Pairs › Chronic Kidney Disease › Valsartan
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Valsartan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. ClinicalTrials.gov lists 8 registered trials linking Valsartan to Chronic Kidney Disease: 1 is currently recruiting; 2 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2008 to 2022. The literature layer holds 13 publications for this pair: 5 Cochrane reviews, 1 meta-analysis, 1 systematic review, 1 randomised controlled trial publication and 5 clinical trial publications. Publication years run from 2024 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Chronic Kidney Disease ranks 534 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: GFR decline averages 2-5 mL/min/year on standard care (ACE/ARB + blood pressure control); progression to end-stage renal disease (ESRD) in ~20-30% at 10 years for moderate CKD; reversal essentially impossible once structural fibrosis established.

Open in Repurposing ExplorerChronic Kidney Disease hubChronic Kidney Disease biomarkers & interventions

Evidence table

Evidence tierA · Strong
Evidence score75.0 (trials 25.0, literature 30.0, tier 15, approved bonus 5.0)
Registered trials8 total: 1 recruiting, 0 active / not yet recruiting, 2 completed, 5 other
Linked publications13 (5 Cochrane reviews, 5 clinical trial publications, 1 meta-analysis, 1 systematic review, 1 randomised controlled trial publication)
Agent typeDrug (Small molecule)
Development stage (any indication)Approved
Mechanism / classinhibitor; inhibitor
Data sourcesDGIdb
Linked via biomarker / targetAGTR1
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT00741585Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment
2008
completedPhase 421,983
NCT00858299The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria
2009
status unknownPhase 4500
NCT02299310Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
2014
status unknownPhase 460
NCT01377285Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD)
2010
status unknownPhase 4350
NCT04263922Huaiqihuang Granule in the Treatment of Primary Glomerulonephritis of Stage CKD3
2020
status unknownPhase 4466
NCT01617681Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD
2012
completedPhase 3127
NCT05279742Enhancing the Natriuretic Peptide System in HFpEF
2022
enrolling by invitationPHASE1, PHASE260
NCT05271448Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography
2021
status unknownNot applicable600

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

Recorded mechanism or class: inhibitor; inhibitor.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Valsartan approved for Chronic Kidney Disease?

Valsartan has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Chronic Kidney Disease would be drug repurposing rather than first-in-human development. This does not mean it is approved for Chronic Kidney Disease. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Valsartan in clinical trials for Chronic Kidney Disease?

ClinicalTrials.gov lists 8 registered trials linking Valsartan to Chronic Kidney Disease: 1 is currently recruiting; 2 have completed; 5 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00741585). It plans or enrolled 21983 participants. Registration activity spans 2008 to 2022.

What does the evidence show for Valsartan in Chronic Kidney Disease?

Valsartan has both completed registered trials and synthesis-level publications linked to Chronic Kidney Disease. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target AGTR1. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Valsartan for Chronic Kidney Disease: evidence, trials and status. OSMF Research Tracker. Updated 2026-07-05. https://research.opensourcemed.info/pairs/chronic-kidney-disease/valsartan.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.